Standard Chartered boosts global ABS team

Rahul Arora joins the bank as managing director responsible for all non-origination related aspects of the business in the United States. Previously, he worked at Banc of America Securities, where he spent six years in a variety of conduit and capital markets roles in the securitisation group. Arora will initially be based in the US and will report to Martin Essenburg, global head of asset securitisation.

In London, Standard Chartered has hired Peter Dow and Nicholas Winther as director and associate, respectively. Dow joins the bank from WestLB, where he was product manager in the ABS and principal finance teams involved in the distribution of ABS and MBS throughout the European institutional investor market. At Standard Chartered, he will be responsible for building the bank’s ABS and MBS global distribution capabilities, and will report to Arora.

Winther joins the bank from JP Morgan Chase, where he spent six years and was involved in ABS transactions for the emerging markets and the corporate real estate sectors, as well as project finance and syndicated finance activities for Europe and the Middle East. At Standard Chartered, he will report to Noel Edison, head of asset securitisation for emerging Europe, Africa, Middle East and South Asia.

“Since the formation of the ABS team last year, we have made significant progress in expanding our presence across our key markets," said Essenburg. "We have now started to strengthen the team with the hires of additional experienced industry practitioners, who will play an important part in bringing our business to the next level."

  • LinkedIn  
  • Save this article
  • Print this page  

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact [email protected] to find out more.

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: